The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

This study is testing whether adding an immunotherapy drug (toripalimab) to radiation therapy before surgery can improve outcomes in patients with operable stage II–IIIA non-small cell lung cancer (NSCLC) — lung cancer that has not yet spread to distant organs. **You may be eligible if...** - You are between 18 and 75 years old - You have non-small cell lung cancer confirmed by pathology - Your cancer is at stage II–IIIA (specifically T1-2N1-2M0 or T3N1M0) - No distant spread has been found on CT or PET/CT scans - Your tumor does not have EGFR, ALK, or ROS1 mutations (specific genetic markers) - You are physically fit for lung surgery **You may NOT be eligible if...** - You have known driver gene mutations (EGFR, ALK, ROS1) - Your cancer has spread outside the chest - You have inadequate organ function Talk to your doctor to see if this trial is right for you.